CUE BIOPHARMA, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.695 USD | -2.59% |
|
-2.01% | -35.42% |
| May. 09 | Cue Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 08 | Transcript : Cue Biopharma, Inc., Q4 2023 Earnings Call, Apr 08, 2024 |
Presenter SpeechAlbert Hwang;Morgan Stanley;Managing Director, Head of Biotechnology Investmen...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells. The Company's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its two oncology drug product candidates, CUE-101 and CUE-102, are exemplary programs from the interleukin 2 (IL-2) based CUE-100 series, and are representative of the HLA-A02 allele, which is prevalent in the United States and western European territories. CUE-101 HLA-A02 is engineered for the treatment of human papillomavirus positive, head and neck squamous cell carcinoma (HNSCC). CUE-102 HLA-A02, targeting Wilms' Tumor 1 protein, an oncofetal antigen known to be over-expressed in more than 20 different cancers.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.74
USD
Average target price
9.4
USD
Spread / Average Target
+440.23%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -35.42% | 84.64M | |
| +8.73% | 114B | |
| +10.88% | 104B | |
| -12.79% | 22.41B | |
| -1.11% | 22.28B | |
| -5.29% | 19.07B | |
| -38.29% | 18B | |
| -4.97% | 17.89B | |
| +7.88% | 14.28B | |
| +36.43% | 12.55B |
- Stock Market
- Equities
- CUE Stock
- News Cue Biopharma, Inc.
- Transcript : Cue Biopharma, Inc. Presents at Morgan Stanley 18th Annual Global Healthcare Conference, Sep-17-2020 05
